JPRN-UMIN000000871已完成未知
Prospective Observational Survey on the Long-Term Effects of the LDL-Apheresis on the Drug Resistant Nephrotic Syndrome - Prospective Observational Survey on the Thrapeutic Effects of the LDL-Apheresis on the Drug Resistant Nephrotic Syndrome - POLARIS Survey
the Japanese Society of Kidney and Lipids Research0 个研究点目标入组 200 人开始时间: 2007年11月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •not applicable
研究者
相似试验
已完成
2 期
ong-Term Safety Follow-Up Of Subjects Previously Enrolled In Rheumatoid Arthritis Studies Of CP-690,550CTRI/2009/091/000722Pfizer Limited300
进行中（未招募）
不适用
A PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE LONG TERM SAFETY AND FUNCTIONAL STATUS OF SUBJECTS WITH RHEUMATOID ARTHRITIS PREVIOUSLY ENROLLED IN STUDIES OF CP-690,550 - N/ACP 690,550 is being developed as a disease modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA).MedDRA version: 8.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2006-006373-25-ATPfizer Ltd, Ramsgate Road, Sandwich CT139NJ, UK300
进行中（未招募）
不适用
A PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE LONG TERM SAFETY AND FUNCTIONAL STATUS OF SUBJECTS WITH RHEUMATOID ARTHRITIS PREVIOUSLY ENROLLED IN STUDIES OF cp 690,550 - N/ACP 690,550 is being developed as a disease modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA).MedDRA version: 8.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2006-006373-25-SEPfizer Ltd, Ramsgate Road, Sandwich CT139NJ, UK300
进行中（未招募）
不适用
A PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE LONG TERM SAFETY AND FUNCTIONAL STATUS OF SUBJECTS WITH RHEUMATOID ARTHRITIS PREVIOUSLY ENROLLED IN STUDIES OF cp 690,550 - N/ACP 690,550 is being developed as a disease modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA).MedDRA version: 8.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2006-006373-25-CZPfizer Inc. 235 East 42nd Street, New York, NY10017300
进行中（未招募）
不适用
A PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE LONG TERM SAFETY AND FUNCTIONAL STATUS OF SUBJECTS WITH RHEUMATOID ARTHRITIS PREVIOUSLY ENROLLED IN STUDIES OF cp 690,550 - N/ACP 690,550 is being developed as a disease modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA).MedDRA version: 8.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2006-006373-25-BGPfizer Inc. 235 East 42nd Street, New York, NY10017300